Evidence map›Paper›PMID 25162623›Full record

ArticlePloS one2014

Upregulation of leukemia inhibitory factor (LIF) during the early stage of optic nerve regeneration in zebrafish.

Kazuhiro Ogai, Ayaka Kuwana, Suguru Hisano, Mikiko Nagashima, Yoshiki Koriyama, Kayo Sugitani, Kazuhiro Mawatari, Hiroshi Nakashima, Satoru Kato

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Leukemia inhibitory factor, a double-edged sword with therapeutic implications in human diseases.Molecular therapy : the journal of the American Society of Gene Therapy · 2023
    Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Kazuhiro OgaiDepartment of Molecular Neurobiology, Graduate School of Medical Science, Kanazawa University, Kanazawa, Ishikawa, Japan; Wellness Promotion Science Center, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Ishikawa, Japan.
Ayaka KuwanaDepartment of Clinical Laboratory Science, Graduate School of Medical Science, Kanazawa University, Kanazawa, Ishikawa, Japan.
Suguru HisanoDepartment of Clinical Laboratory Science, Graduate School of Medical Science, Kanazawa University, Kanazawa, Ishikawa, Japan.
Mikiko NagashimaDepartment of Molecular Neurobiology, Graduate School of Medical Science, Kanazawa University, Kanazawa, Ishikawa, Japan.
Yoshiki KoriyamaDepartment of Molecular Neurobiology, Graduate School of Medical Science, Kanazawa University, Kanazawa, Ishikawa, Japan; Graduate School and Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science, Suzuka, Mie, Japan.
Kayo SugitaniDepartment of Clinical Laboratory Science, Graduate School of Medical Science, Kanazawa University, Kanazawa, Ishikawa, Japan.
Kazuhiro MawatariDepartment of Clinical Laboratory Science, Graduate School of Medical Science, Kanazawa University, Kanazawa, Ishikawa, Japan.
Hiroshi NakashimaDepartment of Clinical Laboratory Science, Graduate School of Medical Science, Kanazawa University, Kanazawa, Ishikawa, Japan.
Satoru KatoDepartment of Molecular Neurobiology, Graduate School of Medical Science, Kanazawa University, Kanazawa, Ishikawa, Japan.
Kanazawa University · JPSuzuka University of Medical Science · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fish retinal ganglion cells (RGCs) can regenerate their axons after optic nerve injury, whereas mammalian RGCs normally fail to do so. Interleukin 6 (IL-6)-type cytokines are involved in cell differentiation, proliferation, survival, and axon regrowth; thus, they may play a role in the regeneration of zebrafish RGCs after injury. In this study, we assessed the expression of IL-6-type cytokines and found that one of them, leukemia inhibitory factor (LIF), is upregulated in zebrafish RGCs at 3 days post-injury (dpi). We then demonstrated the activation of signal transducer and activator of transcription 3 (STAT3), a downstream target of LIF, at 3-5 dpi. To determine the function of LIF, we performed a LIF knockdown experiment using LIF-specific antisense morpholino oligonucleotides (LIF MOs). LIF MOs, which were introduced into zebrafish RGCs via a severed optic nerve, reduced the expression of LIF and abrogated the activation of STAT3 in RGCs after injury. These results suggest that upregulated LIF drives Janus kinase (Jak)/STAT3 signaling in zebrafish RGCs after nerve injury. In addition, the LIF knockdown impaired axon sprouting in retinal explant culture in vitro; reduced the expression of a regeneration-associated molecule, growth-associated protein 43 (GAP-43); and delayed functional recovery after optic nerve injury in vivo. In this study, we comprehensively demonstrate the beneficial role of LIF in optic nerve regeneration and functional recovery in adult zebrafish.

Indexed as

AnimalsDiffusionGAP-43 ProteinGene Expression RegulationJanus Kinase 1Leukemia Inhibitory FactorMorpholinosNerve RegenerationOligonucleotides, AntisenseOptic NerveOptic Nerve InjuriesRecovery of FunctionRetinal Ganglion CellsSignal TransductionSTAT3 Transcription FactorTime FactorsGAP-43 ProteinJanus Kinase 1Leukemia Inhibitory Factorm17 protein, zebrafishMorpholinosOligonucleotides, Antisensestat3 protein, zebrafishSTAT3 Transcription FactorZebrafish Proteins

Identifiers

PMID25162623
PMCPMC4146584
OpenAlexW1968438837

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.